Search research articles
Contact Us
Filters
Showing results (101-110 of 139) with videos related to
Page
of 14
Sort By:
Cancers
|
August 4, 2019
Analysis of AR/ARV7 Expression in Isolated Circulating Tumor Cells of Patients with Metastatic Castration-Resistant Prostate Cancer (SAKK 08/14 IMPROVE Trial)
Ivana Bratic Hench, Richard Cathomas, Luigi Costa, et al.
BJU International
|
March 8, 2024
Safety and quality of cystectomy and pelvic lymph node dissection after neoadjuvant durvalumab and cisplatin/gemcitabine
Luca Afferi, Martin Spahn, Stefanie Hayoz, et al.
Oncoimmunology
|
May 5, 2020
Results of the phase I open label clinical trial SAKK 06/14 assessing safety of intravesical instillation of VPM1002BC, a recombinant mycobacterium Bacillus Calmette Guérin (BCG), in patients with non-muscle invasive bladder cancer and previous failure of conventional BCG therapy
Cyrill A Rentsch, Piet Bosshard, Grégoire Mayor, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 8, 2023
Darolutamide Maintenance in Patients With Metastatic Castration-Resistant Prostate Cancer With Nonprogressive Disease After Taxane Treatment (SAKK 08/16)
Silke Gillessen, Giuseppe Procopio, Stefanie Hayoz, et al.
Swiss Medical Weekly
|
September 6, 2018
Correction to: Baseline characteristics and patterns of care in testicular cancer patients: first data from the Swiss Austrian German Testicular Cancer Cohort Study (SAG TCCS)
Christian Rothermundt, Claudio Thurneisen, Richard Cathomas, et al.
International Journal of Cancer
|
November 29, 2025
Real-world efficacy and toxicity of ipilimumab and nivolumab as a first-line treatment for advanced renal cell carcinoma according to IMDC risk criteria-A multi-center retrospective analysis on behalf of the GUARDIANS group
Hendrik Dinkel, Linus Materna, Ramona Stelmach, et al.
BMC Cancer
|
October 12, 2016
SAKK 24/09: safety and tolerability of bevacizumab plus paclitaxel vs. bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2-negative advanced stage breast cancer - a multicenter, randomized phase III trial
Christoph Rochlitz, Martin Bigler, Roger von Moos, et al.
Cancers
|
April 27, 2024
Development and Validation of an Inflammatory Prognostic Index to Predict Outcomes in Advanced/Metastatic Urothelial Cancer Patients Receiving Immune Checkpoint Inhibitors
Sara Mokbel, Giuilia Baciarello, Pernelle Lavaud, et al.
Clinical Lung Cancer
|
April 7, 2015
Bevacizumab, Pemetrexed, and Cisplatin, or Bevacizumab and Erlotinib for Patients With Advanced Non-Small-Cell Lung Cancer Stratified by Epidermal Growth Factor Receptor Mutation: Phase II Trial SAKK19/09
Oliver Gautschi, Nicholas Mach, Sacha I Rothschild, et al.
Swiss Medical Weekly
|
August 20, 2023
Interdisciplinary Swiss consensus recommendations on staging and treatment of advanced prostate cancer
Arnoud J Templeton, Aurelius Omlin, Dominik Berthold, et al.
Page
of 14
Search research articles
Search
Showing results (101-110 of 139) with videos related to
Sort By:
Page
of 14
Cancers
|
August 4, 2019
Analysis of AR/ARV7 Expression in Isolated Circulating Tumor Cells of Patients with Metastatic Castration-Resistant Prostate Cancer (SAKK 08/14 IMPROVE Trial)
Ivana Bratic Hench, Richard Cathomas, Luigi Costa, et al.
BJU International
|
March 8, 2024
Safety and quality of cystectomy and pelvic lymph node dissection after neoadjuvant durvalumab and cisplatin/gemcitabine
Luca Afferi, Martin Spahn, Stefanie Hayoz, et al.
Oncoimmunology
|
May 5, 2020
Results of the phase I open label clinical trial SAKK 06/14 assessing safety of intravesical instillation of VPM1002BC, a recombinant mycobacterium Bacillus Calmette Guérin (BCG), in patients with non-muscle invasive bladder cancer and previous failure of conventional BCG therapy
Cyrill A Rentsch, Piet Bosshard, Grégoire Mayor, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 8, 2023
Darolutamide Maintenance in Patients With Metastatic Castration-Resistant Prostate Cancer With Nonprogressive Disease After Taxane Treatment (SAKK 08/16)
Silke Gillessen, Giuseppe Procopio, Stefanie Hayoz, et al.
Swiss Medical Weekly
|
September 6, 2018
Correction to: Baseline characteristics and patterns of care in testicular cancer patients: first data from the Swiss Austrian German Testicular Cancer Cohort Study (SAG TCCS)
Christian Rothermundt, Claudio Thurneisen, Richard Cathomas, et al.
International Journal of Cancer
|
November 29, 2025
Real-world efficacy and toxicity of ipilimumab and nivolumab as a first-line treatment for advanced renal cell carcinoma according to IMDC risk criteria-A multi-center retrospective analysis on behalf of the GUARDIANS group
Hendrik Dinkel, Linus Materna, Ramona Stelmach, et al.
BMC Cancer
|
October 12, 2016
SAKK 24/09: safety and tolerability of bevacizumab plus paclitaxel vs. bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2-negative advanced stage breast cancer - a multicenter, randomized phase III trial
Christoph Rochlitz, Martin Bigler, Roger von Moos, et al.
Cancers
|
April 27, 2024
Development and Validation of an Inflammatory Prognostic Index to Predict Outcomes in Advanced/Metastatic Urothelial Cancer Patients Receiving Immune Checkpoint Inhibitors
Sara Mokbel, Giuilia Baciarello, Pernelle Lavaud, et al.
Clinical Lung Cancer
|
April 7, 2015
Bevacizumab, Pemetrexed, and Cisplatin, or Bevacizumab and Erlotinib for Patients With Advanced Non-Small-Cell Lung Cancer Stratified by Epidermal Growth Factor Receptor Mutation: Phase II Trial SAKK19/09
Oliver Gautschi, Nicholas Mach, Sacha I Rothschild, et al.
Swiss Medical Weekly
|
August 20, 2023
Interdisciplinary Swiss consensus recommendations on staging and treatment of advanced prostate cancer
Arnoud J Templeton, Aurelius Omlin, Dominik Berthold, et al.
Page
of 14